Brought to you by 
Epigenomics gets €21mm with Series C private placement
10 Apr 2003
Executive Summary
Epigenomics AG (DNA methylation technology) has raised €21mm ($22.5mm) with the private placement of Series C shares to current investors 3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital, and tbg, and new investor Wellcome Trust.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epigenomics gets €21mm with Series C private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice